The role of interleukin-10 in the pathogenesis of bacterial infection  by van der Poll, Tom et al.
NOTES AND COMMENTS 
The role of interleukin-I0 in the pathogenesis of bacterial 
infection 
Clin Microbiol Ipfict 1997; 3: 605-607 
Introduction 
Infection is associated with enhanced production of 
cytokines, low-molecular-weight proteins important 
for the orchestration of inflammatory processes. 
Research on the role of cytokines in infection was 
boosted by a hallmark publication, now 10 years ago, 
by Tracey and coworkers, demonstrating that neutraliz- 
ation of the cytokine tumor necrosis factor-a (TNF) 
was protective against lethality in a model of severe 
Gram-negative bacteremia in baboons [l]. Since then, 
knowledge of the significance of cytokine production 
during infection has increased considerably. It is clear 
now that cytokines interact in a highly complex 
network, in which they influence each other’s 
production and activity. T N F  is an important pro- 
inflammatory cytokine. The production of these 
inflammation-facilitating cytokines can be inhibited 
by so-called anti-inflammatory cytokines. The most 
important member of this group of mediators is 
interleukin-10 (IL-10). In this article we will briefly 
discuss the relevance of IL-10 for current under- 
standing of the host response to bacterial infection. 
Production of IL- 10 
IL-10 is an 18-kDa polypeptide that can be synthesized 
by T-cells, B-cells, monocytes and macrophages [2]. 
Stimuli that can induce IL-10 production are diverse 
and include bacteria, bacterial products (e.g. endo- 
toxin), parasites, fungi and viruses. In addition, several 
cytokines can enhance IL-10 synthesis, includmg TNF, 
IL-1, IL-6 and IL-12. Elevated plasma levels of IL-10 
have been found in patients with sepsis [3-51. During 
fulnlinant meningococcal septic shock, IL-10 could be 
detected in all patients on admission, while during 
non-meningococcal septic shock, serum IL-10 was 
detectable in 81-83% of patients. One study reporting 
sequential IL-10 measurements during the first 3 days 
after admission documented that plasma IL-10 remained 
high in non-surviving patients, while in survivors, 
plasma IL-10 significantly decreased, suggesting that 
plasma IL-10 may be a relatively stable indicator of the 
severity of the septic insult (51. 
The production of IL-10 during infection can be 
influenced by several mechanisms. In humans and non- 
human primates injected with endotoxin the appear- 
ance of IL-10 in the circulation follows that of TNF, 
and the concentration peaks after 2-3 h [5,6]. Part of 
the endotoxin-induced IL-10 production may be 
regulated by TNE Injection of recombinant T N F  into 
healthy humans induced a modest rise in plasma IL-10 
concentrations, and neutralization of T N F  activity 
in endotoxin-treated chimpanzees by simultaneous 
infusion of an anti-TNF monoclonal antibody attenu- 
ated IL-10 secretion [6].  Further, in human whole 
blood, endotoxin-induced IL-10 production is in part 
TNF-dependent [7]. It should be noted, however, that 
in normal humans elimination of endogenous TNF by 
infusion of a recombinant dimeric T N F  receptor did 
not reduce or only modestly reduced IL-10 release 
during endotoxemia [8,9]. Other endogenous factors 
that may control IL-10 synthesis include prostaglandins, 
cortisol, catecholamines, and, as mentioned above, 
other cytokines [7,10,11]. 
Effects of IL-10 
IL-10 has many different biological activities (Table 1). 
The capacity of IL-10 to inhibit the stimulated produc- 
tion of a number of pro-inflammatory cytokines has 
received much attention. In vitro, IL-10 is a potent 
inhibitor of production of TNF, IL-1, IL-6, IL-8, IL- 
12 and other cytokines [12,13]. In addition, IL-10 
is capable of attenuating the production of a number 
of other mediators of inflammation, including tissue 
factor, nitric oxide and arachidonic acid products 
[14-161. Interestingly, IL-10 may also exert anti- 
inflammatory effects by enhancing the production of 
the IL-1 receptor antagonist, the inain physiologic 
inhibitor of IL-1 [12]. 
Table 1 Biological effects of interleukin-10 
Anti-iiiflaiiminatory a i d  iiiinmunosupprc\sivc effects 
Inhihition of cytokine production by macrophagcs, 
Inhibition of production of reactive nitrogen oxide\ liy 
Inhibition of nrachidotiic . i d  metabolite production 
Inhibition of killing of parasites and  intracellular 1xicteri.i by 
Suppression of procoagulant activity 
Irihibition of class I1 MHC: expression by monocytr\ 
Itihibitioii of inouocyte-depeiideiit T helper cell prolifcratioii 




Stimulation of Kcel l  function\ ( IX .  proliferation, 
Stimulation of development of cytotoxic T-cells 
Stimulation of growth of thymocyte\ md niast cells 
Eiihanceinent of expression of type 1 F c R  fix IgG on monocytes 
iiiimuiioglobuliim secretion, class I1 MHC expression) 
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Several studies have demonstrated the anti-inflam- 
matory potential of IL-10 in vivo. Adrmnistration of 
recombinant IL-10 directly before injection of a lethal 
dose of endotoxin to mice markedly suppressed TNF 
release, and prevented lethality [17]. In healthy humans, 
recombinant human IL-10, given as a single dose of 25 
pg/kg immediately prior to endotoxin, reduced the 
rise in body temperature and in plasma TNF, IL-6 
and IL-8 concentrations [18]. Endotoxin-induced 
granulocyte accumulation in lungs, as determined 
by dynamic granuloscintigrams, was prevented by 
IL- 10 treatment, while granulocyte degradation was 
blunted [ 181. Further, IL- 10 also inhibited the activa- 
tion of the fibrinolytic system and the coagulation 
system [19]. Hence, exogenous IL-10 inhibits inflam- 
mation and reduces mortality in models of endo- 
toxemia. 
Role of endogenous IL-I0 during endotoxemia and infection 
Administration of endotoxin to different species, 
including humans, induces a transient rise in the plasma 
levels of IL-10 [5-9,111. Neutrahzation of this endo- 
genously produced IL-10 in endotoxemic mice resulted 
in an increased production of several pro-inflammatory 
cytokines, including TNF, and an enhanced mortality 
[20,21]. Similarly, IL-10 gene-deficient mice demon- 
strated enhanced mortality after endotoxin injection, 
which was associated with elevated levels of TNF, 
IL-1, IL-6, IL-12, interferon-y and nitrate [22]. 
Interestingly, a number of cytokines may contribute to 
the increased endotoxin-induced lethality in the 
absence of endogenous IL-10, since it can be prevented 
in part by antibodies directed against TNF, interferon- 
y or macrophage inflammatory protein-2 [21,22]. 
Thus, in models of endotoxemia endogenous IL-10 
represents an important autoregulatory mechanism 
controlling the production of pro-inflammatory cyto- 
kines and endotoxin toxicity in vivo. Further, in 
patients with meningococcal septic shock, IL-10 
accounted for most of the monocyte-deactivating 
properties in the circulation, confirming the anti- 
inflammatory role of IL-10 during clinical infection 
Acute models of extensive immune activation do 
not provide insight into the potential beneficial effects 
of pro-inflammatory cytokines at the site of an 
infection, and should therefore be interpreted with 
caution. Indeed, neutralization of IL-10 has been found 
to augment mouse resistance to pneumonia caused by 
Klebsiella pneumoniae or Streptococcus pneumoniae [24,25]. 
It therefore seems likely that IL-I0 produced during at 
least some active infections hampers an adequate pro- 
inflammatory response crucial for effective clearance of 
an infectious agent. The anti-inflammatory properties 
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of IL-10 may also explain why containment of pneu- 
monia was cornpromized further by administration of 
recombinant IL-10 [25]. It should be noted, however, 
that IL-10 does not impair host defense during bacterial 
peritonitis induced by cecal ligation and puncture. 
Cecal ligation and puncture results in spillage of 
bacteria from the gut into the peritoneal cavity, leading 
to polymicrobial peritonitis, and systemic infection. 
Inhibition of IL-10 in this model was associated with 
enhanced lethality, while administration of recom- 
binant IL-10 improved survival [26,27]. 
Conclusion 
The effects of IL-10 during bacterial infections seem 
complex, and are likely to be determined by the source 
of the infection and the functional balance between 
pro-inflammatory and anti-inflammatory forces within 
the cytokine network. During overwhelming immune 
activation, such as after administration of endotoxin 
or during meningococcal septic shock, the anti- 
inflammatory effects of IL-10 can be beneficial. In such 
models, high levels of pro-inflammatory cytokines 
appear in the circulation, and inhibition of their 
systemic effects confers protection against tissue injury 
and lethality. During localized infections, however, 
such as pneumonia, endogenously produced IL-10 
hampers an appropriate host response to invading 
microorganisms. Inhibition of inflammation in patients 
with bacterial infection with recombinant IL-10 may 
therefore be hazardous to some and beneficial to others. 
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